Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY2523355 + pegfilgrastim
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
LY2523355 (litronesib) is an allosteric inhibitor of Eg5 (kinesin spindle protein), a mitotic motor kinesin essential for bipolar spindle formation during cell division. It disrupts mitosis in rapidly dividing cancer cells by inhibiting Eg5 function. Pegfilgrastim is a long-acting recombinant human granulocyte colony-stimulating factor (G-CSF) analog that stimulates the production and maturation of neutrophils to reduce the risk of infection and febrile neutropenia associated with myelosuppressive chemotherapy. The combination is studied in advanced or metastatic cancers to allow higher dosing or mitigate neutropenia caused by LY2523355[1][3][4].
- Brand names
- NeulastaFulphilaFylnetraGrasustekNyvepriaPelgrazPelmegStimfendUdenycaZiextenzo
- Other names
- litronesib
02
Targets
KIF11 (Kinesin Spindle Protein)CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on LY2523355 + pegfilgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY2523355 + pegfilgrastim.